im presenting a phase 3 study (sinus 24 and 52) for the purpose of a medical science liaison job interview. the drug is dupilumab and the indication is chronic rhinosinusitus with nasal polyps. the job interview is to work at Insmed on their drug brensocatib in CRSsNP. my objective to to provide a clear clinical update of the disease state background, the trial design, inclusion/exclusion, outcome measures, results, and an update on the current clinical landscape (some phase 4 tie in and mention of approved competitors (nucala and xolair)
im presenting a phase 3 study (sinus 24 and 52) for the purpose of a medical science liaison job interview. the drug is dupilumab and the indication is chronic rhinosinusitus with nasal polyps. the job interview is to work at Insmed on their drug brensocatib in CRSsNP. my objective to to provide a clear clinical update of the disease state background, the trial design, inclusion/exclusion, outcome measures, results, and an update on the current clinical landscape (some phase 4 tie in and mention of approved competitors (nucala and xolair)
Created using ChatSlide
This presentation delves into the evolving treatment landscape for Chronic Rhinosinusitis (CRS), highlighting insights from Dupilumab’s pivotal SINUS-24 and SINUS-52 studies. Key topics include the heterogeneity of CRS, phenotypes driven by underlying endotypes, and innovative therapeutic approaches, such as IL-4Rα inhibition, for addressing eosinophilic inflammation. With a background as a pharmacist, I will contextualize the safety, efficacy, and clinical implications of biologics, focusing...